Amlodipine Besylate Tablet
Product Images NDC 59762-2135

6 FDA label images from Mylan Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate (NDC 59762-2135). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Amlodipine Besylate Structural Formula (Image 01)

Amlodipine Besylate Structural Formula (Image 01)
Chemical structure diagram of amlodipine besylate, showing its molecular framework with labeled atoms and bonds, including chlorine (Cl), oxygen (O), methyl (CH3), and amino (NH2) groups.*
FDA Label Image

Figure 1 (Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine versus Placebo)

Figure 1 (Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine versus Placebo)
A Kaplan-Meier event rate curve comparing Amlodipine versus Placebo over 24 months. The y-axis represents event rate, and the x-axis represents time in months. The chart includes hazard ratio, confidence intervals, and p-value indicating statistical analysis details.*
FDA Label Image

Figure 2 – Effects On Primary Endpoint Of Amlodipine Versus Placebo Across Sub-groups (Image 03)

Figure 2 – Effects On Primary Endpoint Of Amlodipine Versus Placebo Across Sub-groups (Image 03)
A forest plot displaying hazard ratios with 95% confidence intervals comparing amlodipine besylate and placebo across various patient subgroups. Subgroups include age (<65 and >=65), gender (male and female), baseline sitting systolic blood pressure categories, baseline vessel disease, baseline vessels with stenosis, and PCI-stent strata. The horizontal axis represents hazard ratios from 0.0 to 2.0, with markers indicating whether data favors amlodipine or placebo.*
FDA Label Image

2.5 mg Bottle Label (Image 04)

2.5 mg Bottle Label (Image 04)
Label for amlodipine besylate tablets 2.5 mg by Mylan Pharmaceuticals Inc. The label indicates a package containing 90 tablets, branded as Greenstone. Storage instructions specify controlled room temperature of 59° to 86°F (15° to 30°C) and protection from light. The label includes dosage information stating each tablet contains amlodipine besylate equivalent to 2.5 mg amlodipine, along with regulatory and lot number details.*
FDA Label Image

5 mg Bottle Label (Image 05)

5 mg Bottle Label (Image 05)
Label for amlodipine besylate tablets, 5 mg strength, by Mylan Pharmaceuticals Inc. The label indicates 90 tablets in the package under Greenstone brand. Storage instructions specify room temperature 59° to 86°F, protected from light, with dispensing in USP, light-resistant, child-resistant containers. The label also includes dosage and use notes and packaging details including lot and expiry barcode information.*
FDA Label Image

10 mg Bottle Label (Image 06)

10 mg Bottle Label (Image 06)
Label for amlodipine besylate tablets, 10 mg strength, by Mylan Pharmaceuticals Inc. The package contains 90 tablets, marked as GREENSTONE® BRAND. Storage instructions specify controlled room temperature 59° to 86°F, protection from light, and dispensing in child-resistant containers. The NDC is 59762-2135-9, with a barcode and lot/expiration details printed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.